Canada markets closed

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0233-0.0009 (-3.93%)
At close: 01:46PM EDT

Curative Biotechnology, Inc.

1825 NW Corporate Boulevard
Suite 110
Boca Raton, FL 33431
United States
561 907 8990

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul M. MichaelsPresident & Executive Chairman335.39kN/A1967
Mr. I. Richard Garr Esq., J.D.CEO, CFO, Principal Accounting Officer & General Counsel455.39kN/A1953
Mr. Pam BisikirskiVice President of CommunicationsN/AN/AN/A
Dr. Ronald Bordens Ph.D.Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.

Corporate Governance

Curative Biotechnology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.